Ispronicline (AZD-3480): A Comprehensive Review of a Selective α4β2 Nicotinic Receptor Agonist from Clinical Promise to Discontinuation

Compound Identification and Physicochemical Properties

Ispronicline is an investigational small molecule drug developed for the treatment of cognitive and neurological disorders.[1][ Throughout its development, it has been referred to by several names and codes, which are essential for navigating the scientific and clinical literature. A comprehensive understanding of its identity and chemical properties provides the foundation for interpreting its pharmacological and clinical profile.]

Nomenclature and Regulatory Identifiers

The compound was assigned the International Nonproprietary Name (INN) and United States Adopted Name (USAN) of Ispronicline.[1] During its preclinical and clinical development phases, it was known by several developmental codes, most prominently TC-1734 (by Targacept), AZD-3480 (by AstraZeneca), and RJR-1734 (by R.J. Reynolds).[2] The IUPAC nomenclature for the molecule is (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine, with minor variations such as (E,2S)-N-methyl-5-(5-propan-2-yloxy-3-pyridinyl)pent-4-en-2-amine also appearing in chemical databases.[2][ For unambiguous identification, a set of regulatory and database identifiers has been assigned, which are consolidated in Table 1.]

Chemical Structure and Properties

Ispronicline is a small molecule with the chemical formula $C_{14}H_{22}N_{2}O$ and a molar mass of approximately 234.34 g·mol⁻¹.[2] Its structure features a pyridine ring linked to an amine-containing pentene chain, with specific stereochemistry and double bond geometry that are critical for its biological activity. As a research chemical, it is described as an oily liquid, colorless to light yellow in appearance.[4] For laboratory use and long-term stability, it requires storage under dry, dark conditions at refrigerated ($0 - 4$ °C) or frozen ($-20$ °C) temperatures.[4] The compound exhibits good solubility in organic solvents like dimethyl sulfoxide (DMSO) but requires specific formulations involving co-solvents such as PEG300 and Tween-80 for preparation of aqueous solutions suitable for in vivo administration.[5]

Table 1: Ispronicline - Key Identifiers and Physicochemical Properties
Attribute	Value
Generic Name (INN/USAN)	Ispronicline
Developmental Codes	TC-1734, AZD-3480, RJR-1734 1
DrugBank ID	DB16205 2
CAS Number	252870-53-4 2
PubChem CID	9824145 2
IUPAC Name	(2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine 3
Drug Type	Small Molecule 1
Molecular Formula	$C_{14}H_{22}N_{2}O$ 2
Molar Mass	234.343 g·mol⁻¹ 3
SMILES	CC@@HNC
InChIKey	RPCVIAXDAUMJJP-PZBABLGHSA-N
Physical Appearance	Oily liquid

Preclinical Pharmacology and Mechanism of Action

[The therapeutic rationale for Ispronicline was grounded in the well-established role of the cholinergic system in cognitive processes and the pathological loss of cholinergic neurons and receptors in neurodegenerative diseases like Alzheimer's Disease (AD). Ispronicline was developed as a next-generation therapeutic designed to directly and selectively modulate this system, aiming for enhanced efficacy and improved tolerability over previous approaches.]

Primary Mechanism of Action: Selective α4β2 nAChR Partial Agonist

[Ispronicline's primary mechanism of action is as a partial agonist at neuronal nicotinic acetylcholine receptors (nAChRs). Specifically, it targets the $\alpha4\beta2$ nAChR subtype, which is the most abundantly expressed nAChR in the mammalian central nervous system (CNS) and is critically involved in modulating the release of neurotransmitters like acetylcholine and dopamine, thereby influencing attention, learning, and memory.]

[The designation as a "partial agonist" is a key feature of its design. Unlike full agonists (e.g., nicotine), which maximally activate the receptor, a partial agonist produces a submaximal response. This characteristic is intended to provide a ceiling effect, stimulating cholinergic neurotransmission to a therapeutic level while mitigating the risk of overstimulation that can lead to receptor desensitization—a prolonged, functionally inactive state—and a higher incidence of adverse effects. This approach was conceived to create a wider therapeutic window compared to earlier, non-selective full agonists.]

Receptor Binding Profile and Selectivity

[Ispronicline's pharmacological profile is distinguished by its high affinity and remarkable selectivity for its target receptor.]

• High Affinity: In vitro[ binding assays demonstrated that Ispronicline binds to the human $\alpha4\beta2$ nAChR with high affinity, with a reported inhibition constant ($K_i$) of 11 nM.]
• Functional Potency:[ Its agonist activity was confirmed in functional assays using human embryonic kidney (HEK293) cells expressing the target receptor, where it elicited a response with a half-maximal effective concentration ($EC_{50}$) of 106 nM.]
• High Selectivity:[ A critical aspect of Ispronicline's design was its high selectivity for the $\alpha4\beta2$ subtype over other nAChR subtypes. It shows significantly lower activity at the neuronal $\alpha7$ nAChR and the peripheral (ganglionic) $\alpha3\beta4$ nAChR.]

[This selectivity profile represents a deliberate and successful exercise in rational drug design. Earlier attempts to harness the pro-cognitive effects of nicotinic stimulation were often thwarted by poor tolerability, including cardiovascular and gastrointestinal side effects, which are largely mediated by the activation of peripheral nAChRs such as the $\alpha3\beta4$ subtype found in autonomic ganglia. By engineering a molecule with a strong preference for the central $\alpha4\beta2$ receptor, the developers aimed to uncouple the desired CNS effects from the undesirable peripheral effects, a hypothesis that was later validated by the drug's favorable safety profile in human trials.]

In Vitro and In Vivo Pharmacodynamic Effects

[Preclinical studies provided a robust body of evidence supporting Ispronicline's potential as a CNS therapeutic. The compound demonstrated a triad of beneficial effects:]

1. Cognition-Enhancing (Nootropic) Effects:[ In numerous rodent models, Ispronicline consistently demonstrated memory-enhancing and cognition-enhancing properties, forming the primary basis for its clinical investigation in disorders of cognitive impairment like Age-Associated Memory Impairment (AAMI) and AD.]
2. Neuroprotective Properties:[ Beyond symptomatic improvement, preclinical data indicated that Ispronicline possessed neuroprotective effects. This suggested a potential for disease modification in neurodegenerative conditions, a significant theoretical advantage over existing symptomatic treatments like acetylcholinesterase inhibitors, which merely prolong the action of existing acetylcholine.]
3. Antidepressant Effects:[ An antidepressant-like profile was also observed in preclinical models, suggesting a broader potential utility in neuropsychiatric disorders.]

Further in vivo[ evidence confirmed that Ispronicline effectively penetrates the CNS and engages its target. Administration to rats resulted in the induction of c-Fos, an immediate early gene product used as a marker of neuronal activation, in specific forebrain regions like the paraventricular nucleus of the hypothalamus. This provided direct physiological evidence of the drug's central activity following systemic administration.]

Human Pharmacokinetics and Metabolism

[Phase I clinical studies in healthy volunteers provided essential data on the absorption, distribution, metabolism, and excretion (ADME) of Ispronicline, defining its behavior in the human body and guiding the design of subsequent efficacy trials.]

Absorption, Distribution, Metabolism, and Excretion (ADME) Profile

[Ispronicline was developed for oral administration and exhibited pharmacokinetic properties consistent with a CNS-active drug.]

• Absorption:[ Following oral dosing, the drug was rapidly absorbed, with peak plasma concentrations ($C_{max}$) achieved approximately 1 to 2 hours post-administration.]
• Distribution:[ The compound was designed to be "brain-selective," effectively crossing the blood-brain barrier to exert its effects on central nAChRs, a property supported by its observed CNS effects in both preclinical and clinical settings.]
• Metabolism:[ Ispronicline undergoes metabolism, yielding at least one identified active metabolite, TC-1784, formed via N-desalkylation. Clinical trial protocols provided strong evidence for the involvement of the cytochrome P450 enzyme CYP2D6 as a major metabolic pathway. The protocol for an ADHD trial (NCT00683462) explicitly mandated the exclusion of subjects identified as CYP2D6 slow metabolizers through genotyping. Furthermore, a separate Phase I trial (NCT00713765) was designed specifically to investigate the pharmacokinetic interaction between Ispronicline and donepezil in both extensive and poor metabolizers of CYP2D6.]
• Elimination:[ The drug has a relatively short terminal elimination half-life ($t_{1/2}$), ranging from 3 to 5.3 hours after single doses and from 2.7 to 8.8 hours after repeated dosing. Consistent with its short half-life, no drug accumulation was observed after 10 days of once-daily administration. Renal clearance was determined to be a minor route of elimination for both Ispronicline and its metabolite TC-1784.]

Dose-Response and Pharmacokinetic Variability

[The pharmacokinetic data revealed two critical characteristics that influenced Ispronicline's clinical development. First, a high degree of interindividual variability was observed across all pharmacokinetic parameters. This variability is a significant challenge in drug development, as it can lead to inconsistent drug exposure and, consequently, variable efficacy and tolerability across a patient population. The proactive decision to exclude CYP2D6 poor metabolizers from the ADHD trial was a direct strategic response to mitigate this known variability in a small, exploratory study, thereby increasing the chance of detecting a clear efficacy signal. However, this design choice also means that the positive results from that specific trial may not be fully generalizable to a broader population that includes individuals with different metabolic phenotypes.]

[Second, a striking disconnect emerged between the drug's pharmacokinetic profile and its pharmacodynamic effects. While the pharmacokinetic half-life in humans was only a few hours, preclinical studies in rodents reported that the cognition-enhancing effects could last for 18 to 48 hours. This temporal disparity suggests that Ispronicline's mechanism of action is not reliant on continuous receptor occupancy. Instead, it points toward a "hit-and-run" mechanism, where a short period of receptor engagement by the drug triggers durable downstream effects, such as lasting changes in synaptic plasticity or neural circuit function, that persist long after the drug has been cleared from the body. This has important implications for dosing strategies, suggesting that once-daily administration could be sufficient despite the short half-life.]

Clinical Development and Efficacy Evaluation

[Ispronicline underwent a broad Phase II clinical development program, exploring its efficacy in three distinct CNS indications: Age-Associated Memory Impairment (AAMI), Alzheimer's Disease (AD), and adult Attention-Deficit/Hyperactivity Disorder (ADHD). The program yielded a complex and divergent set of results, with clear evidence of efficacy in some conditions but a decisive failure in its lead indication.]

Table 2: Summary of Key Phase II Clinical Trials for Ispronicline
Indication	NCT Identifier	Study Design	Patient Population	Doses Studied	Primary Endpoint(s)	Key Outcome Summary
Age-Associated Memory Impairment (AAMI)	NCT00109564	Double-blind, placebo-controlled, crossover	76 elderly subjects with AAMI	50-150 mg/day	CDR computerized test battery	Positive: Significant improvement in attention and episodic memory, most marked at 50 mg.
Alzheimer's Disease (AD)	NCT00501111, NCT01466088	Double-blind, placebo- and active-controlled, parallel-group	567 patients with mild-to-moderate AD	5, 20, 35/100 mg/day	ADAS-Cog	Negative/Inconclusive: Failed to meet primary endpoint; neither Ispronicline nor active control (donepezil) separated from placebo.
Adult ADHD	NCT00683462	Double-blind, placebo-controlled, 3-way crossover	24 adults with ADHD	5, 50 mg/day	Stop Signal Task (SST), CAARS-INV	Positive: Significant improvement on both cognitive (SST) and clinical (CAARS) measures at 50 mg.

Investigation in Age-Associated Memory Impairment (AAMI)

[The initial clinical validation for Ispronicline's pro-cognitive effects came from studies in subjects with AAMI, a condition characterized by subjective memory complaints associated with normal aging. A Phase II, double-blind, placebo-controlled crossover study (NCT00109564) evaluated ascending oral doses (50-150 mg) administered once daily for three weeks. Efficacy was measured using the Cognitive Drug Research (CDR) computerized test battery, a sensitive tool for detecting changes in cognitive domains.]

[The results were highly encouraging. A beneficial effect on cognition was observed, with the most pronounced improvements seen at the 50 mg dose, particularly on measures of attention and episodic memory. A separate 16-week, parallel-group study in AAMI subjects reinforced these findings, showing that the 50 mg dose was statistically superior to placebo on the CDR Power of Attention and Quality of Episodic Memory factors, as well as on a subjective Subject Global Impression (SGI) scale. The 25 mg dose demonstrated a weaker signal, primarily on attention. These studies provided the first human proof-of-concept for Ispronicline as a cognition-enhancing agent.]

Investigation in Alzheimer's Disease (AD)

[Based on the promising AAMI data and the strong mechanistic rationale, Ispronicline advanced into a large, pivotal Phase IIb dose-finding study for mild-to-moderate AD. This 12-week, randomized, parallel-group trial enrolled 567 patients and was designed to rigorously assess efficacy. It included five arms: three doses of Ispronicline (5 mg, 20 mg, and a 35/100 mg titration), an active comparator (donepezil 10 mg), and placebo. The primary outcome measure was the change from baseline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the standard cognitive endpoint for AD clinical trials.]

[The trial ultimately failed to meet its primary endpoint. At the end of 12 weeks, no dose of Ispronicline demonstrated a statistically significant improvement over placebo on the ADAS-Cog score. Critically, the active comparator, donepezil—an approved and effective treatment for AD—also failed to separate from placebo on this primary measure. While some positive signals were observed on secondary endpoints (e.g., MMSE, ADCS-CGIC) for the 20 mg dose, the failure on the primary endpoint led to the study being deemed "inconclusive" and failing to establish proof-of-concept.]

[The failure of the active control in this study is a crucial detail. The purpose of an active comparator is to validate a trial's methodology and sensitivity; if a trial cannot detect the effect of a known-effective drug, its results regarding an investigational drug are uninterpretable. This suggests that the trial's failure may have been due to methodological issues, such as patient selection, rather than a true lack of efficacy of Ispronicline. A post-hoc analysis excluding patients with very mild disease (who have little room for measurable cognitive decline) showed a trend toward improvement for both Ispronicline and donepezil, lending further support to the idea that the trial design may have obscured a real treatment effect. Nevertheless, this ambiguous result from a large and expensive trial proved to be a fatal blow to the development program.]

Investigation in Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

[In parallel, Ispronicline was evaluated as a novel, non-stimulant treatment for adult ADHD. An exploratory Phase II trial (NCT00683462) used a rigorous 3-way crossover design in 24 adults, comparing two doses of Ispronicline (5 mg/day and 50 mg/day) against placebo. The study employed co-primary endpoints to capture both cognitive and clinical effects: the Stop Signal Task (SST), a measure of response inhibition, and the investigator-rated Conners Adult ADHD Rating Scale (CAARS-INV).]

[The results were unequivocally positive. The 50 mg/day dose led to statistically significant improvements on both primary endpoints. Participants showed improved performance on the SST, indicating enhanced executive control, and a significant reduction in their total ADHD symptom score on the CAARS-INV. Significant benefits were also seen on subscales measuring inattention, memory problems, and emotional lability/impulsivity. The 5 mg dose was ineffective. This trial provided strong evidence that Ispronicline, at an appropriate dose, could be a viable therapeutic option for adult ADHD.]

Safety and Tolerability Profile

[A key strength of Ispronicline, demonstrated consistently across its entire clinical program, was its favorable safety and tolerability profile. This outcome validated the core drug design principle of achieving CNS effects while minimizing peripheral side effects through receptor subtype selectivity.]

Overall Assessment

[In Phase I studies with healthy volunteers and Phase II studies across diverse patient populations, Ispronicline was consistently reported as safe and well-tolerated at therapeutic doses. Tolerability was favorable for doses up to 100-150 mg, with adverse events becoming more common at higher dose levels.]

Adverse Event (AE) Profile

[The most common treatment-emergent adverse events were CNS-related and generally of mild to moderate intensity.]

• Most Frequent AEs:[ Dizziness (or light-headedness) and headache were the most frequently reported side effects across multiple studies.]
• Other AEs:[ In the AD trial, the overall AE profile for Ispronicline was comparable to placebo and notably featured fewer gastrointestinal AEs (nausea, vomiting, diarrhea) than the active comparator, donepezil. This further highlights the success of the selective design in avoiding common cholinergic side effects. Serious Adverse Events (SAEs) were rare and their incidence was similar between the drug and placebo groups.]

Clinical Safety Assessments

[Objective safety monitoring revealed no signals of concern. Comprehensive assessments, including clinical laboratory tests (hematology, biochemistry), urinalysis, vital signs, and cardiovascular monitoring via electrocardiograms (ECG) and Holter monitoring, showed no clinically significant changes attributable to Ispronicline treatment. The absence of cardiovascular effects was particularly significant, confirming that the high selectivity for central $\alpha4\beta2$ nAChRs over peripheral subtypes successfully avoided the side effects that had limited the development of earlier nicotinic agonists.]

Analysis of Development Discontinuation and Future Perspectives

[The development of Ispronicline was ultimately discontinued despite a successful rational design, a strong preclinical profile, a favorable safety record, and positive proof-of-concept data in two clinical indications. The decision to halt the program provides a compelling case study in the complexities and strategic risks of modern pharmaceutical development, particularly in the challenging field of neuroscience.]

The Decisive Factor: Insufficient Efficacy in Alzheimer's Disease

[The primary driver for the discontinuation was the outcome of the large and costly Phase IIb trial in mild-to-moderate AD. The failure to meet the primary endpoint of a statistically significant improvement on the ADAS-Cog created an insurmountable barrier to progression. In the high-risk, high-cost landscape of AD drug development, an "inconclusive" result is often a functional failure, as it provides an insufficient basis to justify the immense financial investment required for a global Phase III program. The drug's performance was not demonstrably superior to the existing standard of care, donepezil, which itself failed to show efficacy in the trial, making the path forward untenable.]

Contextualizing the Failure: Broader Challenges in nAChR and AD Drug Development

[Ispronicline's failure in AD was not an isolated event but rather reflective of broader challenges that have plagued this therapeutic area.]

• Diminished Target Engagement:[ A fundamental problem for nAChR-targeted therapies in AD is the progressive loss of cholinergic neurons and the downregulation of nAChRs in the brains of patients. It is highly plausible that by the time a patient presents with symptomatic mild-to-moderate AD, the density of the $\alpha4\beta2$ receptor target is too low for a selective agonist to exert a clinically meaningful effect. The drug may have been tested too late in the disease process.]
• Inherent Pharmacological Hurdles:[ The phenomenon of receptor desensitization with prolonged agonist exposure remains a key challenge for this drug class. It is possible that over a 12-week trial, this process attenuated the drug's initial therapeutic effect.]
• The Complexity of AD Pathophysiology:[ Ispronicline's failure is part of a long history of nAChR-targeting compounds that have not succeeded in AD. This underscores the immense difficulty of treating a multifactorial disease where pathologies related to amyloid-beta and tau may play more dominant roles in driving cognitive decline than the cholinergic deficit alone.]

Unexplored Potential and Concluding Remarks

[The discontinuation of Ispronicline presents a paradox. A drug with a validated mechanism, excellent safety, and statistically significant, positive clinical data in both AAMI and adult ADHD was abandoned. This highlights a potential pitfall of a "lead indication" development strategy, where failure in a high-value but high-risk indication (AD) can lead to the termination of a program, leaving potentially viable treatments for other conditions unexplored.]

[In conclusion, Ispronicline stands as a testament to successful rational drug design. Its molecular architecture achieved the intended goal of selective central nAChR modulation with an excellent safety profile. It demonstrated clear biological activity and therapeutic potential in human studies of age-related cognitive decline and adult ADHD. However, its development was ultimately derailed by an ambiguous result in a pivotal AD trial, a trial whose own methodological validity is questionable. The story of Ispronicline is a cautionary tale of how a promising therapeutic candidate can fall victim not to its own flaws, but to the profound scientific, strategic, and financial challenges inherent in developing drugs for neurodegenerative diseases. Its potential as a safe and effective non-stimulant treatment for ADHD remains a significant, and likely permanent, unanswered question in neuropharmacology. The compound's history is documented across numerous patents related to its chemical structure and therapeutic use, and in key publications that detail its preclinical and clinical journey.]

Works cited

1. Ispronicline - Drug Targets, Indications, Patents - Synapse, accessed October 19, 2025, https://synapse.patsnap.com/drug/d270dd7b8f9748c4b28128b149abbc24
2. Ispronicline | C14H22N2O | CID 9824145 - PubChem, accessed October 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ispronicline
3. Ispronicline - Wikipedia, accessed October 19, 2025, https://en.wikipedia.org/wiki/Ispronicline
4. Ispronicline | AZD3480 | CAS#252870-53-4 | nicotinic receptor partial agonist | MedKoo, accessed October 19, 2025, https://www.medkoo.com/products/11692
5. Ispronicline (TC-1734) | α4β2 nAChR Agonist - MedchemExpress.com, accessed October 19, 2025, https://www.medchemexpress.com/ispronicline.html
6. 252870-53-4|(S,E)-5-(5-Isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine|BLD Pharm, accessed October 19, 2025, https://www.bldpharm.com/products/252870-53-4.html
7. Ispronicline | CAS NO.:252870-53-4 - GlpBio, accessed October 19, 2025, https://www.glpbio.com/ispronicline.html
8. Product Data Sheet - MedchemExpress.com, accessed October 19, 2025, https://file.medchemexpress.com/batch_PDF/HY-10063/Ispronicline-DataSheet-MedChemExpress.pdf
9. Ispronicline Completed Phase 2 Trials for Alzheimer's Disease (AD) Treatment - DrugBank, accessed October 19, 2025, https://go.drugbank.com/drugs/DB16205/clinical_trials?conditions=DBCOND0049114&phase=2&purpose=treatment&status=completed
10. Ispronicline (TC-1734, AZD-3480) | nAChR agonist | Buy from Supplier AdooQ®, accessed October 19, 2025, https://www.adooq.com/ispronicline.html
11. Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture - Semantic Scholar, accessed October 19, 2025, https://pdfs.semanticscholar.org/ae4e/c0729ab80f33f2942927c72943e1b5c3db00.pdf
12. Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update - PMC - PubMed Central, accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6379052/
13. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new ..., accessed October 19, 2025, https://pubmed.ncbi.nlm.nih.gov/16809797/
14. Pozanicline: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 19, 2025, https://go.drugbank.com/drugs/DB05458
15. Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors | Journal of Medicinal Chemistry - ACS Publications, accessed October 19, 2025, https://pubs.acs.org/doi/10.1021/jm401937a
16. Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties - PubMed, accessed October 19, 2025, https://pubmed.ncbi.nlm.nih.gov/17192610/
17. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic ..., accessed October 19, 2025, https://www.semanticscholar.org/paper/Effects-of-TC-1734-(AZD3480)%2C-a-selective-neuronal-Dunbar-Boeijinga/4c382f34700249f99224efa155bed0a8eac7b8c1
18. Ispronicline (Targacept) - PubMed, accessed October 19, 2025, https://pubmed.ncbi.nlm.nih.gov/16425673/
19. Study Details | NCT00683462 | An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) | ClinicalTrials.gov, accessed October 19, 2025, https://clinicaltrials.gov/study/NCT00683462
20. Effect of ispronicline, a neuronal nicotinic... : Journal of Psychopharmacology - Ovid, accessed October 19, 2025, https://www.ovid.com/journals/jpsyc/abstract/10.1177/0269881107066855~effect-of-ispronicline-a-neuronal-nicotinic-acetylcholine
21. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) - CORE, accessed October 19, 2025, https://core.ac.uk/outputs/1041146605/?source=2
22. (PDF) Effects of AZD3480 on Cognition in Patients with Mild-to ..., accessed October 19, 2025, https://www.researchgate.net/publication/49777359_Effects_of_AZD3480_on_cognition_in_patients_with_mild-to-moderate_Alzheimer's_disease_A_phase_IIb_dose-finding_study
23. AZD3480, a novel nicotinic receptor agonist, for the treatment of ..., accessed October 19, 2025, https://pubmed.ncbi.nlm.nih.gov/23856296/
24. A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI) - ClinicalTrials.Veeva, accessed October 19, 2025, https://ctv.veeva.com/study/a-safety-and-efficacy-study-of-ispronicline-tc-1734-112-in-subjects-with-age-associated-memory-imp
25. Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects, accessed October 19, 2025, http://media.corporate-ir.net/media_files/irol/17/178332/GenevaPoster.pdf
26. Ispronicline Completed Phase 2 Trials for Attention Deficit Hyperactivity Disorder (ADHD) Treatment | DrugBank Online, accessed October 19, 2025, https://go.drugbank.com/drugs/DB16205/clinical_trials?conditions=DBCOND0041782&phase=2&purpose=treatment&status=completed
27. Investigational drugs for the treatment of AD: what can we learn from negative trials? - PMC, accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3226276/